RBBP8NL

Across TCGA pan-cancer cohorts, RBBP8NL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBBP8NL data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBBP8NL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RBBP8NL expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, STAD, and LIHC are the cancer types where RBBP8NL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.176	0.671	.035	18	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
LIHC	OS	Median	All	0.156	0.774	.007	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.667	.015	4	view →
LGG	OS	Median	All	0.300	0.830	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBBP8NL–HNSC (OS)

Open the HNSC breakdown →